Recommended Free Tools
The nuclear-medicine equipment market is projected to expand through 2035, but the headline value depends on what analysts include. Future Market Insights estimates a market of USD 2.6 billion in 2025 reaching USD 3.9 billion in 2035, a 4.1% compound annual growth rate (CAGR). GE HealthCare cites a much broader nuclear-medicine projection of approximately $7.8 billion in 2024 to more than $30.7 billion by 2034. Those figures are not interchangeable: the publishers use different definitions of nuclear medicine and equipment.
Across the forecasts, the common growth engine is the move toward theranostics, hybrid PET/CT and SPECT/CT, wider radiopharmaceutical access, quantitative software, and more standardized clinical workflows.
As an Amazon Associate I earn from qualifying purchases.
How big is the nuclear medicine equipment market in 2035?
Future Market Insights puts the equipment market at USD 2.6 billion in 2025 and USD 3.9 billion in 2035, implying a 4.1% CAGR. Its segmentation gives a useful view of where current revenue sits: SPECT accounts for 33.8% of 2025 equipment revenue, oncology for 38.4% of application revenue, and hospitals for 47.6% of end-user revenue.
A separate International Atomic Energy Agency (IAEA) estimate focused on SPECT and SPECT/CT valued that market at $1.41 billion in 2018 and forecast approximately $1.934 billion in 2025, or about a 4.64% CAGR. GE HealthCare’s 2026 communication uses a broader market boundary, projecting approximately $7.8 billion in 2024 to more than $30.7 billion by 2034.
#1 Best Overall
| Estimate | Starting value | Ending value | Growth measure | Scope and date |
|---|---|---|---|---|
| Future Market Insights | USD 2.6 billion (2025) | USD 3.9 billion (2035) | 4.1% CAGR | Nuclear-medicine equipment; 2025 forecast |
| IAEA | $1.41 billion (2018) | Approximately $1.934 billion (2025) | About 4.64% CAGR | SPECT/SPECT-CT market; publication accessed 2026 |
| GE HealthCare | Approximately $7.8 billion (2024) | More than $30.7 billion (2034) | Not stated | Broader nuclear-medicine projection; 2026 statement |
The figures should therefore be used as directional evidence, not combined into one market total. Equipment-only estimates can exclude radiopharmaceutical production, software, services, or treatment infrastructure that broader forecasts count.
What is driving nuclear medicine equipment market growth?
Theranostics links diagnosis to treatment
Theranostics uses a molecular target first for imaging and then for treatment with a related radionuclide. This approach requires more than a camera: providers need quantitative imaging, dosimetry, radiopharmaceutical supply, scheduling, radiation-safety processes, and coordination among nuclear medicine, oncology, physics, pharmacy, and billing teams.
GE HealthCare describes the field as moving “from early innovation to large-scale clinical implementation.” Its cited portfolio illustrates the integrated stack: StarGuide digital SPECT/CT, MIM LesionID Pro and MIM KineticID software, and MINItrace Magni for onsite PET-tracer and radiometal production. These are examples of the capabilities buyers are evaluating, not independent proof of market share.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Rank #2
- Ideal for Gifting
- Ideal for a bookworm
- Compact for travelling
Hybrid imaging improves localization and treatment decisions
SPECT/CT and PET/CT pair functional or molecular information with anatomical localization. The combination supports staging, prognosis, treatment planning, response monitoring, and more confident interpretation than either information source alone. The IAEA describes hybrid imaging as a way to tailor interventions to an individual patient in line with personalized medicine.
Radiopharmaceutical access is becoming strategic infrastructure
Tracer availability, production capacity, transport, shelf life, and regulatory handling can determine whether an expensive scanner is fully utilized. Technetium-99m remains central: the IAEA says it is used in about 85% of nuclear-medicine diagnostic procedures worldwide, with more than 30 million patients examined annually. Onsite or regional production can reduce dependence on long logistics chains, while short-lived isotopes make scheduling and quality control critical.
AI and quantitative analytics turn images into measurements
Modern systems increasingly automate reconstruction, lesion segmentation, kinetic modeling, dosimetry, and longitudinal response assessment. The commercial value is not only faster image reading; standardized measurements can help clinicians compare scans over time and support therapy selection. Buyers should verify validation in their intended indication, interoperability with the existing PACS and electronic record, and how much staff intervention remains necessary.
Are SPECT/CT and PET/CT the future of nuclear medicine?
Hybrid systems are the central modality trend, but standalone systems remain relevant where cost, space, throughput, or a specific protocol favors them. SPECT continues to represent the largest single equipment segment in the Future Market Insights forecast, at 33.8% of 2025 revenue. The IAEA also describes a renewed clinical role for SPECT/CT.
| Platform | Typical information | Common uses | Key buying questions |
|---|---|---|---|
| Standalone SPECT | Functional distribution of gamma-emitting tracers | Cardiology, bone and endocrine imaging, selected neurology protocols | Detector configuration, resolution, reconstruction, service access |
| SPECT/CT | Functional data with CT localization and attenuation correction | Oncology staging, cardiology, infection and inflammation, theranostic planning | CT dose, quantitative accuracy, motion correction, room shielding |
| PET/CT | Highly sensitive molecular imaging plus anatomical localization | Oncology staging and response, neurology, cardiology, radiopharmaceutical therapy planning | Time-of-flight performance, scan speed, tracer supply, throughput |
| PET/MRI | Molecular imaging with high soft-tissue contrast and MRI sequences | Selected oncology, neurology, pediatrics, and research workflows | Capital and facility requirements, attenuation correction, specialist staffing |
Hybrid imaging does not eliminate the need for protocol expertise. A system’s clinical value depends on tracer selection, acquisition parameters, reconstruction, interpretation, and the ability to connect results to a treatment decision.
Where is demand concentrated?
Oncology
Oncology is the largest application in the Future Market Insights forecast, at 38.4% of 2025 application revenue. PET/CT and SPECT/CT can support staging, prognosis, therapy selection, and response monitoring, while theranostic programs add dosimetry and repeat quantitative imaging.
Rank #4
Cardiology and neurology
Cardiology remains an important use case for perfusion and viability studies, and neurology uses molecular imaging for disorders in which anatomy alone may not explain symptoms. The appropriate platform depends on the tracer, protocol, and required spatial or temporal resolution.
Hospitals and distributed access
Hospitals account for an estimated 47.6% of 2025 end-user revenue. At the same time, mobile and community-access models can extend PET capacity beyond a main hospital campus. Such models shift attention toward scheduling, transport, uptime, radiopharmaceutical logistics, and remote interpretation.
Do these 3 things before closing this tab:
1Fix the driver behind crashes, sound loss and screen glitches2Clear out junk files and repair common Windows errors3Scan for outdated or missing drivers - takes under a minuteHow are theranostics changing equipment and workflow?
- Identify the target and imaging protocol. The diagnostic tracer must demonstrate target expression and produce images suitable for treatment selection.
- Quantify disease burden. Segmentation, standardized uptake or count measurements, and kinetic analysis help establish a baseline.
- Plan administered activity and dosimetry. Therapy requires radiation-safety review, organ-at-risk assessment, and repeat measurements where clinically indicated.
- Coordinate production and delivery. Short-lived radionuclides require reliable manufacturing, quality release, transport, and patient scheduling.
- Monitor response and toxicity. Follow-up imaging and laboratory data are integrated with oncology decisions.
This workflow explains why a scanner purchase alone may not create a theranostics service. Facilities also need trained staff, shielding, hot-lab or radiopharmacy capability, validated software, regulatory procedures, and referral volume.
Best Value
- It can be a gift option
- Comes with secure packaging
- Helpful in various ways
Which companies make nuclear medicine equipment?
Future Market Insights lists Siemens Healthineers, Philips Healthcare, GE Healthcare, Digirad, Mediso, DDD-Diagnostics, Neusoft, SurgicEye, and CMR Naviscan among market participants. GE HealthCare says its Omni Legend PET/CT has more than 500 installations worldwide and also highlights StarGuide digital SPECT/CT and its MIM software products.
These names cover different parts of the value chain. A procurement team should distinguish scanner manufacturers from software suppliers, radiopharmaceutical and cyclotron providers, service organizations, and calibration-product vendors rather than treating them as interchangeable competitors.
What should buyers compare before choosing a system?
- Modality fit: standalone SPECT, SPECT/CT, PET/CT, or PET/MRI for the intended clinical mix.
- Clinical coverage: oncology, cardiology, neurology, and planned theranostic indications.
- Quantification: lesion segmentation, kinetic modeling, dosimetry, motion correction, and longitudinal analytics.
- Throughput: scan duration, reconstruction speed, automation, patient preparation, and daily capacity.
- Interoperability: DICOM behavior, PACS and electronic-record integration, cybersecurity, and data export.
- Radiopharmaceutical ecosystem: tracer availability, onsite production, delivery distance, shelf life, and backup suppliers.
- Facility requirements: room dimensions, shielding, power, HVAC, CT infrastructure, hot-lab space, and regulatory approvals.
- Serviceability: acceptance testing, preventive maintenance, calibration, uptime commitments, software updates, and parts availability.
- Total cost: capital expenditure plus staffing, isotopes, service contracts, compliance, replacement parts, and reimbursement assumptions.
Why calibration and quality assurance create recurring demand
Every installed camera requires routine checks to maintain quantitative and diagnostic reliability. Calibration phantoms, reference standards, radioactive sources, shielding, and radiopharmacy accessories support acceptance testing and ongoing SPECT/PET quality assurance. INIS states that most radioactive calibration products are replaced after approximately 18 months to two years, creating a recurring consumables and compliance requirement rather than a one-time equipment sale.
As of September 2025, INIS reported at least 131 countries and more than 29,000 installed SPECT/PET cameras. That installed base helps explain why service, calibration, and replacement cycles can grow even when new scanner purchases follow a steadier path.
What could limit growth through 2035?
Expansion depends on more than demand for precision imaging. Nuclear-medicine programs face shortages of trained technologists and physicists, isotope supply interruptions, licensing and shielding requirements, high capital costs, and uneven reimbursement. PET and theranostic services can also be constrained by tracer shelf life and the distance between production and treatment sites.
Market forecasts carry additional uncertainty because their boundaries differ. Vendor announcements indicate product direction but are not independent market validation. The most resilient investments will be those tied to measurable patient volume, dependable radiopharmaceutical access, validated quantitative workflows, and a service plan that covers the equipment’s full operating life.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
